Changes in P-glycoprotein expression in gastric carcinoma with respect to distant gastric mucosa may be influenced by p53

Cancer

Volumn 89, Issue 1, 2000, Pages 21-28

  Lacueva, F Javier ^a,c,d   Calpena, Rafael ^a   Medrano, Justo ^a   Teruel, Ana ^a,c   Mayol, M Jose ^a   Graells, M Luisa ^a   Camarasa, M Vicenta ^b   Perez Vazquez, M Teresa ^a   Ferragut, Jose A ^b  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^d Departamento de Patologia y Cirugia   (Spain)

Author keywords

Gastric carcinoma; Nontumor gastric mucosa; P glycoprotein; p53

Indexed keywords

GLYCOPROTEIN P; PROTEIN P53;

ARTICLE; CLINICAL ARTICLE; CORRELATION FUNCTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; STOMACH CARCINOMA; TISSUE PREPARATION; TUMOR RESISTANCE;

GASTRIC MUCOSA; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; P-GLYCOPROTEIN; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034235381     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000701)89:1<21::AID-CNCR4>3.0.CO;2-T     Document Type: Article

References (54)

1. Wanebo HJ, Kennedy BJ, Chmiel J, Steele G, Winchester D, Osteen R. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg 1993;218:583-92.
2. Siewert JR, Bötcher K, Roder JR, Busch R, Hermanek P, Meyer HJ. Prognostic relevance of systematic lymph node dissection in gastric carcinoma. Br J Surg 1993;80:1015-8.
3. Wils JA, Klein HO, Wagener DJTh, Bleiberg H, Reis H, Korsten F, et al. Sequential high dose methotrexate and fluoracil combined with doxorubicin. A step ahead in the treatment of advanced gastric cancer: a trial of the European Organization of Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991;5:827-31.
4. Hermans J, Bonenkamp JJ, Boon MC, Bunt AMG, Ohyama S, Sasako M, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993;11:1441-7.
5. Findlay M, Cunningham D, Norman A, Mansi J, Nicolson M, Hickish T, et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluoracil (ECF). Ann Oncol 1994; 5:609-16.
6. Ajani JA, Mansfield PF, Ota DM. Potentially resectable gastric carcinoma: current approaches to staging and preoperative therapy. World J Surg 1995;19:216-20.
7. Fink U, Schumacher C, Stein HJ, Busch R, Feussner H, Dittler HJ, et al. Preoperative chemotherapy for stage III-IV gastric carcinoma: feasibility, response and outcome after complete resection. Br J Surg 1995;82:1248-52.
8. Pastan I, Gottesman MM. Multidrug resistance. Annu Rev Med 1991;42:277-86.
9. Bellamy WT. P-glycoprotein and multidrug resistance. Annu Rev Pharmacol Toxicol 1996;36:161-83
10. Robey-Cafferty SS, Rutledge ML, Bruner JM. Expression of a multidrug resistance gene in esophageal adenocarcinoma. Correlation with response to chemotherapy and comparison with gastric adenocarcinoma. Am J Clin Pathol 1990;93: 1-7.
11. Vollrath V, Chianale J, Gonzalez S, Duarte I, Andrade L, Ibanez L. Multidrug resistance gene and P-glycoprotein expression in gastric adenocarcinoma and precursor lesions. Virchows Arch B Cell Pathol 1991;60:133-8.
12. Dhar DK, Nagasue N, Yoshimura H, Tachibana M, Tahara H, Matsuura H, et al. Overexpression of P-glycoprotein in untreated AFP-producing gastric carcinoma. J Surg Oncol 1995; 60:50-4.
13. Lacueva FJ, Teruel A, Calpena R, Medrano J, Mayol MJ, Perez-Vazquez MT, et al. Detection of P-glycoprotein in frozen and paraffin-embedded gastric adenocarcinoma tissues using a panel of monoclonal antibodies. Histopathology 1998;32:328-34.
14. van der Valk P, van Kallen CK, Ketelaars H, Broxterman HJ, Scheffer G, Kuiper CM, et al. Distribution of multidrug resistance associated P-glycoprotein in normal and neoplastic human tissues. Ann Oncol 1990;1:56-64.
15. Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumours: consensus recommendations. Cancer Res 1996;56:3010-20.
16. Cordon-Cardo C. Immunohistochemical analysis of P-glycoprotein expression in normal and tumour tissues in humans. In: Robinson IB, editor. Molecular and cell biology of multidrug resistance in tumour cells. New York: Plenum Press, 1991:303-16.
17. van Kalken CK, Pinedo HM, Giaccone G. Multidrug resistance form the clinical point of view. Eur J Cancer 1991;27: 1481-6.
18. Kanamaru H, Kakehi Y, Yoshida O, Nakanishi S, Pastan I, Gottesman MM. MDR1 RNA levels in human renal cell carcinomas: correlation with grade and prediction of reversal of doxorubicin resistance by quinidine in tumor explants. J Natl Cancer Inst 1989;81:844-9.
19. Mizoguchi T, Yamada K, Furukawa T, Hidaka K, Hisatsugu T, Shimazu H, et al. Expression of the MDR1 gene in human gastric and colorectal carcinomas. J Natl Cancer Inst 1990; 82:1679-83.
20. Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK, Kuszak JR, et al. Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 1991;51: 2720-6.
21. Linn SC, Honkoop AH, Hoekman K, van der Valk P, Pinedo HM, Giaccone G. p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Br J Cancer 1996;74:63-8.
22. Monden M, Abe S, Sutoh I, Hishikawa Y, Kinugasa S, Nagasue N. Prognostic significance of the expressions of metallothionein, glutathione-S-transferase-n, and P-glycoprotein in curatively resected gastric cancer. Oncology 1997;54: 391-9.
23. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991;351:453-6.
24. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54: 4855-78.
25. Renault B, van der Broek M, Fodde R, Wijnen J, Pellegata NS, Amadori D, et al. Base transitions are the most frequent genetic changes at p53 in gastric cancer. Cancer Res 1993; 53:2614-7.
26. Poremba C, Yandell DW, Huang Q, Little JB, Mellin W, Schmid KW, et al. Frequency and spectrum of p53 mutations in gastric cancer - a molecular genetic and immunohistochemical study. Virchows Arch 1995;426:447-55.
27. Starzynska T, Bromley M, Ghosh A, Stern PL. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 1992;66:558-62.
28. Hurlimann J, Saraga EP. Expression of p53 protein in gastric carcinomas. Association with histologic type and prognosis. Am J Surg Pathol 1994;18:1247-53.
29. Joypaul BV, Hopwood D, Newman EL, Qureshi S, Grant A, Ogston SA, et al. The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocardnoma. Br J Cancer 1994;69:943-6.
30. Gabbert HE, Müller W, Schneiders A, Meier S, Hommel G. The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer 1995;76:720-6.
31. Chin KV, Ueda K, Pastan I, Gotesman MM. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992;255:459-62.
32. Zastawny RL, Salvino R, Chen J, Benchimol S, Ling V. The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53. Oncogene 1993;8:1529-35.
33. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
34. Cascinu S, Graziano F, Del Ferro E, Staccioli MP, Ligi M, Carnevali A, et al. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer 1998;83:1917-22.
35. Thottassery JV, Zambetti GP, Arimori K, Schuetz EG, Schuetz JD. p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc Natl Acad Sci USA 1997;94:11037-42.
36. Goldsmith ME, Gudas JM, Schneider E, Cowan H. Wild type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line. J Biol Chem 1995;270:1894-8.
37. Strauss BE, Haas M. The region 3′ to the major transcriptional start site of the MDR1 downstream promoter mediates activation by a subset of mutant p53 proteins. Biochem Biophys Res Commun 1995;217:333-40.
38. Ogretmen B, Safa AR. Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells. Oncogene 1997;14:499-506.
39. Schneider J, Rubio MP, Barbazan MJ, Rodriguez-Escudero FJ, Seizinger BR, Castresana JS. P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors. J Natl Cancer Inst 1994;86:850-5.
40. De Angelis P, Stokke T, Smedshammer L, Lothe RA, Lehne G, Chen Y, et al. P-glycoprotein is not expressed in a majority of colorectal carcinomas and is not regulated by mutant p53 in vivo. Br J Cancer 1995;72:307-11.
41. Ng IOL, Lam KY, Ng M, Kwong DLW, Sham JST. Expression of P-glycoprotein, a multidrug-resistance gene product, is induced by radiotherapy in patients with oral squamous cell carcinoma. Cancer 1998;83:851-7.
42. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 1965;64:31-49.
43. Beahrs OH, Henson DE, Hutter RW, Kennedy BJ, editors. American Joint Committee on Cancer. Manual for staging of cancer. 4th ed. Philadelphia: JB Lippincott, 1992:63-6.
44. Hsu SM, Raine L, Fanger H. Comparative study of the immunoperoxidase and avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Pathol 1981;75:734-40.
45. Soto F, Planells-Cases R, Canaves JM, Ferrer-Montiel AV, Aleu J, Gamarro F, et al. Possible coexistance of two independent mechanisms contributing to anthracycline resistance in leukemia P388 cells. Eur J Cancer 1993;29:2144-50.
46. Rao VV, Anthony DC, Piwnica-Worms D. Multidrug resistance P-glycoprotein monoclonal antibody JSB-1 crossreacts with pyruvate carboxylase. J Histochem Cytochem 1995; 43:1187-92.
47. Rao VV, Anthony DC, Piwnica-Worms D. MDR1 gene-specific monoclonal antibody C494 cross-reacts with pyruvate carboxylase. Cancer Res 1994;54:1536-41.
48. Toth K, Vaughan MM, Slocum HK, Fredericks WJ, Chen YF, Arredondo MA, et al. Comparison of an immunoperoxidase "sandwich" staining method and western blot detection of P-glycoprotein in human cell lines and sarcomas. Am J Pathol 1992;140:1009-16.
49. Baker RM, Fredericks WJ, Chen Y, Murawski MJ, Meegan RL, Rustum YM, et al. Detection of P-glycoprotein in human tumors by immunoblot analyses. In: Mihich E, editor. Drug resistance: mechanisms and reversal. Trento: John Libbey CIC, 1989:167-80.
50. Gerlach JH, Bell DR, Karakousis C, Slocum HK, Kartner N, Rustum YM, et al. P-glycoprotein in human sarcoma: evidence for multidrug resistance. J Clin Oncol 1987;5: 1452-60.
51. Shiao Y, Rugge M, Correa P, Lehmann HP, Scheer WD. p53 alteration in gastric precancerous lesions. Am J Pathol 1994; 144:511-7.
52. Craanen ME, Block P, Dekker W, Offerhaus GJA, Tygat GN. Chronology of p53 protein accumulation in gastric carcinogenesis. Gut 1995;36:848-52.
53. Endo K, Maehara Y, Kusumoto T, Ichiyoshi Y, Kuwano M, Sugimachi K. Expression of multidrug-resistance-associated protein (MRP) and chemosensitivity in human gastric cancer. Int J Cancer 1996;68:372-6.
54. Takebayashi Y, Akiyama S, Natsugor S, Hokita S, Niwa K, Kitazono M, et al. The expression of multidrug resistance protein in human gastrointestinal tract carcinomas. Cancer 1998;82:661-6.